Posts tagged stock price
RBC upgrades CRH Medical to OP

RBC Capital Markets upgraded CRH Medical (TSX:CRH; NYSE MKT:CRHM) to “outperform” from “sector perform” but lowered its price target to $6 (Canadian) from $8.50. The stock closed at $4.07 on July 20.

Read More
Profound Medical to expand collaboration with Royal Philips’, acquire Sonalleve unit

Profound Medical (OTCQX:PRFMF; TSXV:PRN) has agreed to expand an existing collaboration with Royal Philips (NYSE:PHG; AEX:PHIA) and acquire Philips’ Sonalleve MR-HIFU business, establishing Profound as a market leader in magnetic resonance (MR) ultrasound ablation therapy.

Read More
Leerink upgrades Achillion to OP

Leerink upgraded Achillion Pharmaceuticals (NASDAQ:ACHN) to “outperform” from “market perform” and raised its price target to $6 from $4. The stock closed at $3.78 on May 17.

Read More
Roth resumes coverage of Galectin Therapeutics

Roth Capital Partners resumed coverage of Galectin Therapeutics (NASDAQ:GALT) with a “buy” rating and $3 price target. The stock closed at $1.52 on Friday.

“In our opinion, Phase 1 data demonstrated Galectin’s GR-MD-02’s positive effect on NASH fibrosis biomarkers,” writes analyst Sa’ar Yaniv.

Read More